For example, in early-stage CKD a streamlined yet unguided fixed-dose polypill built around an SGLT2 inhibitor plus an ARB may offer practical benefits by delivering broad, guideline conforming protection (upon validation in a properly powered clinical trial). This evidence concerns the gene SLC5A2 and chronic kidney disease.